Advanced Search

 

Study ID Status Title Patient Level Data
ARIA3001_4 Completed A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel Group Study of the Efficacy and Safety of Dutasteride GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on Open-Label Treatment Phase). Study Listed on ClinicalStudyDataRequest.com
ARIA3002 Completed A Randomized, double-blind, placebo-controlled, two year parallel group study of the efficacy and safety of GI198745 0.5 mg in the treatment and prevention of progression of benign prostatic hyperplasia Study Listed on ClinicalStudyDataRequest.com
ARIA3002_2 Completed A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on 2 Year Data). Study Listed on ClinicalStudyDataRequest.com
ARIA3002_4 Completed A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on Open-Label Treatment Phase). Study Listed on ClinicalStudyDataRequest.com
ARIB2002 Completed A Randomised, Double-Blind, Placebo-Controlled, Double-Dummy Study of Dutasteride (GI198745) in Subjects Awaiting Transurethral Resection of the Prostate (TURP) for Treatment of Benign Prostatic Hyperplasia (BPH)
ARIB3003 Completed A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of GI198745 in the treatment and modification of progression of benign prostatic hyperplasia Study Listed on ClinicalStudyDataRequest.com
ARIB3003 Completed A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of GI198745 in the treatment and modification of progression of benign prostatic hyperplasia Study Listed on ClinicalStudyDataRequest.com
ARIB3003_4 Completed A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel-Group Study of the Efficacy and Safety of GI198745 in the Treatment and Modification of Progression of Benign Prostatic Hyperplasia, Followed by a Two Year Open-Label GI198745 Treatment Phase (Report on Open-Label Treatment Phase). Study Listed on ClinicalStudyDataRequest.com
ARIB3004 Completed A six-month, randomised, double-blind, placebo-controlled, parallel group study to evaluate the effects of repeat dose oral GI198745 on detrusor pressure and urinary flow in patients with lower urinary tract symptoms suggestive of bladder outlet obstruction, with optional six month open-label extension Study Listed on ClinicalStudyDataRequest.com
ARIB3004_1 Completed A Six-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects of Repeat Dose Oral Dutasteride GI198745 on Detrusor Pressure and Urinary Flow in Patients with Lower Urinary Tract Symptoms Suggestive of Bladder Outlet Obstruction, with Optional Six Month Open-Label Extension. Study Listed on ClinicalStudyDataRequest.com
ARIF4012 Completed Multicentric, randomised, double-blind, double-dummy, parallel-group clinical trial evaluating short-term efficacy and safety of dutasteride compared to finasteride in patients presenting with BPH when switching from finasteride
ART108053 Completed An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA (2.5mg subcutaneously) for the Treatment of Patients with Acute Symptomatic Isolated Superficial Thrombophlebitis of the Lower Limbs to prevent Thromboembolic Complications
Article-31 Completed Article 31 referral analyses of GSK’s clinical trial data to evaluate the risk of suicide, suicidal thoughts and behaviours, and self-harm, with particular attention to potential risk factors including age and gender
AUG102821 Completed A study to determine PK profiles of AUGMENTIN XR in adolescents weight at least 40 kg receiving Augmentin XR BID for 10 days Study Listed on ClinicalStudyDataRequest.com
AVA102670 Completed A 54 week, double-blind, randomised, placebo-controlled, parallel group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response in APOE4-stratified subjects with mild to moderate Alzheimer's disease Study Listed on ClinicalStudyDataRequest.com
AVA102672 Completed A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to donepezil on cognition and overall clinical response in APOE ε4-stratified subjects with mild to moderate Alzheimer’s disease. Study Listed on ClinicalStudyDataRequest.com
AVA102675 Terminated An open-label extension to study AVA102670 and AVA102672, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) as adjunctive therapy on cognition in subjects with mild to moderate Alzheimer's disease. Study Listed on ClinicalStudyDataRequest.com
AVA102677 Terminated An open-label extension to study AVA105640, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer's disease. Study Listed on ClinicalStudyDataRequest.com
AVA104617 Completed An open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's Disease Study Listed on ClinicalStudyDataRequest.com
AVA109939 Completed An Open-Label, Randomized, Crossover Study to the dose proportionality of RSG XR in healthy volunteers in fasting conditions
AVALON Completed Avandia Longitudinal Observational Network (AVALON)
AVD100521 Completed A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type 2 Diabetes Mellitus and Cardiovascular Disease (APPROACH) Study Listed on ClinicalStudyDataRequest.com
AVD102209 Completed A Randomized, Double-Blind, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone Compared to Insulin Plus Placebo for 24 Weeks in Subjects with Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin
AVD104742 Completed Clinical evaluation of Rosiglitazone Malate (BRL49653C) in Patients with Type 2 Diabetes Mellitus (Monotherapy) - Double-Blind Comparative Study of Rosiglitazone Maleate vs. Pioglitazone Hydrochloride and Placebo - Study Listed on ClinicalStudyDataRequest.com
AVD105248 Completed Clinical Evaluation of Rosiglitazone Maleate (BRL49653C) in Patients with Type 2 Diabetes Mellitus (Combination Therapy with Sulfonyl Urea) - A Placebo-Controlled Double-Blind Study - Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.